Phase 3 Trial Finds Phentolamine Eye Drops Improve Night Vision Symptoms

A phase 3, double-masked, randomized, placebo-controlled trial (LYNX-1) evaluated 0.75% phentolamine ophthalmic solution (POS) administered nightly for 14 days in 145 subjects with dim light vision disturbances and reduced mesopic low-contrast visual acuity. The trial reported significant improvement in mesopic low-contrast visual acuity at Day 8 and Day 15 with POS versus placebo, along with significant reductions in patient-reported severity of dim light disturbances, glare, halos, and starburst; adverse events were predominantly mild and transient with no significant difference in conjunctival hyperemia or vital signs between arms. The authors state these findings suggest POS may warrant further clinical investigation as a pharmacologic approach for this condition.

Most relevant for: Patients with reduced mesopic low-contrast vision and dim light disturbances, including those who have undergone keratorefractive surgery.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.